Bioptik Technology (TWO:4161) — Market Cap & Net Worth
Market Cap & Net Worth: Bioptik Technology (4161)
Bioptik Technology (TWO:4161) has a market capitalization of $41.93 Million (NT$1.33 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #22649 globally and #1387 in its home market, demonstrating a -1.11% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Bioptik Technology's stock price NT$22.25 by its total outstanding shares 59808203 (59.81 Million). Also see Bioptik Technology asset portfolio for a full breakdown of the balance sheet.
Bioptik Technology Market Cap History: 2015 to 2026
Bioptik Technology's market capitalization history from 2015 to 2026. Data shows change from $110.67 Million to $41.93 Million (-8.57% CAGR). Also see 4161 cash generation efficiency for how efficiently the company converts equity into cash flow.
Bioptik Technology Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Bioptik Technology's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check 4161 stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.06x
Bioptik Technology's market cap is 0.06 times its annual revenue
Latest Price to Earnings (P/E) Ratio
0.66x
Bioptik Technology's market cap is 0.66 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $77.11 Million | $476.39 Million | -$33.72 Million | 0.16x | N/A |
| 2018 | $57.17 Million | $519.55 Million | $26.39 Million | 0.11x | 2.17x |
| 2019 | $61.69 Million | $566.42 Million | $5.25 Million | 0.11x | 11.75x |
| 2020 | $48.67 Million | $485.60 Million | -$59.99 Million | 0.10x | N/A |
| 2021 | $51.92 Million | $737.89 Million | $22.59 Million | 0.07x | 2.30x |
| 2022 | $53.14 Million | $767.75 Million | $48.50 Million | 0.07x | 1.10x |
| 2023 | $60.58 Million | $828.50 Million | $85.71 Million | 0.07x | 0.71x |
| 2024 | $57.94 Million | $865.34 Million | $93.57 Million | 0.07x | 0.62x |
| 2025 | $47.01 Million | $837.19 Million | $71.19 Million | 0.06x | 0.66x |
Competitor Companies of 4161 by Market Capitalization
Companies near Bioptik Technology in the global market cap rankings as of September 18, 2026. Review Bioptik Technology tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Bioptik Technology by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #125 globally with a market cap of $177.99 Billion USD.
- Medtronic PLC (NYSE:MDT): Ranked #228 globally with a market cap of $109.30 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #229 globally with a market cap of $109.23 Billion USD.
- Medtronic plc (SA:MDTC34): Ranked #239 globally with a market cap of $104.84 Billion USD ( R$534.32 Billion BRL).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #125 | Abbott Laboratories | NYSE:ABT | $177.99 Billion | $102.36 |
| #228 | Medtronic PLC | NYSE:MDT | $109.30 Billion | $92.60 |
| #229 | Stryker Corporation | NYSE:SYK | $109.23 Billion | $284.76 |
| #239 | Medtronic plc | SA:MDTC34 | $104.84 Billion | R$208.39 |
Bioptik Technology Historical Marketcap From 2015 to 2026
Between 2015 and today, Bioptik Technology's market cap moved from $110.67 Million to $ 41.93 Million, with a yearly change of -8.57%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$41.93 Million | -10.82% |
| 2025 | NT$47.01 Million | -18.86% |
| 2024 | NT$57.94 Million | -4.35% |
| 2023 | NT$60.58 Million | +14.01% |
| 2022 | NT$53.14 Million | +2.35% |
| 2021 | NT$51.92 Million | +6.67% |
| 2020 | NT$48.67 Million | -21.11% |
| 2019 | NT$61.69 Million | +7.91% |
| 2018 | NT$57.17 Million | -25.86% |
| 2017 | NT$77.11 Million | -22.15% |
| 2016 | NT$99.05 Million | -10.50% |
| 2015 | NT$110.67 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Bioptik Technology was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $41.93 Million USD |
| MoneyControl | $41.93 Million USD |
| MarketWatch | $41.93 Million USD |
| marketcap.company | $41.93 Million USD |
| Reuters | $41.93 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Bioptik Technology
Bioptik Technology Incorporation engages in the manufacturing, wholesale, and retail of biotechnology and medical equipment in Taiwan and internationally. The company offers blood glucose, cholesterol, uric acid, hemoglobin and acid multi-function monitoring systems under the EasyMate, EasySure, and EasyTouch brand name, as well as PeTouch, a glucose monitoring system for dogs and cats. It also p… Read more